Bill Sibold, Madrigal Pharmaceuticals CEO
August 7, 2024 07:45 AM EDTUpdated 11:21 AM
Pharma
Marketing

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

Nicole DeFeudis

Editor

Madri­gal Phar­ma­ceu­ti­cals is “off to a strong start” with its re­cent­ly ap­proved MASH drug Rezd­if­fra, CEO Bill Si­bold said on Wednes­day. The com­pa­ny pulled …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times